BPC-157 (Body Protection Compound 157): Pentadecapeptide Research Data

What Is BPC-157?

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a stable fragment of a larger protein originally identified in human gastric juice — "Body Protection Compound" is the descriptor the Sikiric group attached to the parent material based on its experimental gastroprotective behaviour. The synthetic 15-residue sequence used in modern research is what the literature refers to as "BPC-157".^[1]

Standard chemistry: molecular formula C₆₂H₉₈N₁₆O₂₂, molecular weight 1419.55 g/mol, CAS number 137525-51-0. Free-base and acetate-salt forms both circulate in the literature; the acetate salt is the form most often referenced in compounding-pharmacy filings and the form the FDA's 2026 PCAC docket evaluates alongside the free base.^[5]

The peptide's research interest comes from two unrelated properties: it is unusually stable in human gastric juice (the experimental observation that named the parent compound), and its rodent-model phenotype is reproducibly broad — tendon, ligament, gut-mucosal, vascular, and central-nervous-system models all show signals in the Sikiric body of work.^[2] Both of those features make it an attractive tool compound. Neither makes it a finished medicine.

Mechanism of Action: Nitric Oxide, Angiogenesis & Growth Factor Modulation

The mechanistic narrative for BPC-157 was assembled across roughly two decades of rodent work, primarily by Sikiric and colleagues at the University of Zagreb, with mechanistic detail added by independent vascular-biology groups. Three pathway clusters anchor it:

• Nitric oxide (NO) system modulation. Multiple rodent studies report that BPC-157 counteracts experimental NO-system dysregulation, including the effects of L-NAME-induced eNOS blockade and L-arginine excess. The peptide appears to restore endothelial function and blood-pressure homeostasis in those models, with effects that fail to appear when NO synthesis is fully blocked — implicating the NO axis as part of the working mechanism rather than as a downstream artefact.^[2]
• VEGF / eNOS-driven angiogenesis. Hsieh et al. and follow-on vascular-biology work reported that BPC-157 upregulates VEGFR2 expression and downstream eNOS-mediated angiogenic signalling in endothelial cell models, with corresponding capillary outgrowth in injury and ischaemia models.^[6] This is the strongest mechanistic candidate for the recurrent "improved healing" phenotype seen in tendon, ligament, and gut-mucosal models.
• FAK-paxillin and growth-factor signalling. In tendon and fibroblast preparations, BPC-157 has been linked to focal-adhesion kinase and paxillin phosphorylation, accelerating fibroblast outgrowth and migration in scratch-wound assays. This is the cytoskeletal-repair correlate of the angiogenic signal.^[7]

Adjacent literature describes interactions with dopaminergic, serotonergic, and GABAergic systems in rodent CNS models, which the Sikiric group has used to argue for a broader stabilising role across multiple injury contexts.^[2] No single receptor has been cleanly identified as the BPC-157 target. The honest summary is that the mechanism is multi-pathway and partially resolved, not single-receptor and clean.

Preclinical Evidence: Tendon, Ligament, GI, and Vascular Models

The BPC-157 preclinical body is large, mostly rodent, and concentrated in four model families.

1. Tendon and ligament injury

Rat Achilles tendon transection and medial collateral ligament injury models from the Sikiric group and independent orthopaedic labs report accelerated functional recovery, increased tenocyte outgrowth, and earlier reappearance of organised collagen in BPC-157-treated animals compared with vehicle controls. Mechanistically, the FAK-paxillin signal and VEGF-driven micro-vascular ingrowth are the most common explanations offered in those papers.^[7]

2. Gastrointestinal mucosa

The original "gastroprotection" framing comes from rodent models of ethanol-induced gastric lesions, cysteamine-induced duodenal ulceration, and short-bowel syndrome. BPC-157 reduced mucosal damage scores and accelerated re-epithelialisation in those models, which is the experimental observation that named the parent material.^[1][2]

3. Vascular and ischaemia models

Hsieh et al. and related vascular-biology work showed angiogenic responses in chick chorioallantoic membrane assays, capillary-outgrowth assays, and rodent ischaemic-limb and venous-occlusion models. The recurring observation is faster restoration of perfusion, with VEGFR2 upregulation as the proposed proximal cause.^[6]

4. Central nervous system models

A smaller body of rodent CNS work reports interactions with dopaminergic, serotonergic, and GABAergic signalling, with claims around stabilisation in models of haloperidol-induced catalepsy, MPTP-induced parkinsonism, and amphetamine-induced disturbances. This literature is less independently replicated than the gut and vascular work and should be read with corresponding caution.^[2]

Across all four families, the model species is almost always rat or mouse, the route is most often intraperitoneal or oral via drinking water, and the dose ranges used in animals do not translate cleanly to human-scale dosing — a point the McGuire 2025 narrative review makes explicitly.^[4]

First Human Data — Lee & Burgess 2025 IV Pilot

Until 2025, BPC-157 had no published human pharmacology of any kind. Lee and Burgess closed that gap — narrowly — with a two-subject IV pilot in healthy adults, published in 2025 and indexed at PMID 40131143.^[3]

The study dosed up to 20 mg BPC-157 intravenously in two healthy adult participants and reported no adverse events across the study period. It is a safety-orientated first-in-human signal, not an efficacy study, and the authors frame it accordingly. Two subjects cannot tell you about rare adverse events, dose-response, or pharmacokinetics with any rigour. What the paper does establish is that the regulatory and ethical case for further human work is no longer purely hypothetical — it now has a published anchor.^[3]

For research-context framing, the Lee & Burgess pilot is the single most-cited new data point in the BPC-157 literature since 2023. Any source treating it as proof of clinical efficacy is overreading the paper. Any source ignoring it as if BPC-157 still has zero human data is underreading the paper.

2025 Narrative Review: McGuire et al. — "Still Investigational"

McGuire et al. published a narrative review in Current Reviews in Musculoskeletal Medicine in August 2025 (PMC12446177), explicitly framing BPC-157 in the orthopaedic-and-recovery context where it is most commonly discussed.^[4]

The review's headline conclusion is that BPC-157 remains investigational. The authors acknowledge the consistency and breadth of the preclinical signal, particularly in tendon and gastrointestinal models, and they cite the Lee & Burgess 2025 IV pilot as the first concrete piece of human safety evidence. They also flag three honest limits: the absence of registered Phase 2 and Phase 3 efficacy trials, the lack of a published human pharmacokinetic profile, and the unresolved dose-translation question between rodent and human scales. Their summary recommendation is caution in clinical recommendation pending registered trial data.^[4]

That summary is the clean reference frame for describing BPC-157 in 2026: real preclinical signal, real first human safety touchpoint, no registered efficacy trials, no validated human dosing.

Analytical Records & Evidence Boundaries

A BPC-157 analytical record can describe molecular identity and sample composition, but each method answers a limited question:

• Identity. Sequence information and mass spectrometry can support that the analysed material is consistent with the expected molecule.
• Purity. HPLC can estimate chromatographic purity under the stated method; it does not by itself establish identity or the amount of peptide present.
• Content. A separate quantitative assay is needed to report how much analyte is present.
• Microbiology. Sterility and endotoxin are separate tests. They cannot be inferred from an HPLC purity percentage.

None of those records converts an investigational peptide into an approved medicine or establishes safety, efficacy, or suitability for human or veterinary use. This page does not sell, source, or provide handling instructions for BPC-157.

What the BPC-157 Literature Does Not Yet Give You

Cautious reading of BPC-157 requires acknowledging four real gaps.

• No registered Phase 2 or Phase 3 efficacy trial. A clinicaltrials.gov search at the time of writing returns no BPC-157-specific late-stage efficacy registration. The Lee & Burgess 2025 IV pilot is a two-subject safety touchpoint, not an efficacy trial.^[3]
• No published human pharmacokinetic profile. Half-life, distribution, route-specific bioavailability, and metabolism in humans are not characterised in the public literature in the way they are for established protein medicines. Rodent-model dose ranges do not translate cleanly to the human scale, and the McGuire 2025 review names this explicitly as a translational gap.^[4]
• Mechanism is multi-pathway and partially resolved. The NO axis, VEGF/eNOS angiogenic signalling, and FAK-paxillin growth-factor work each have independent support, but no single receptor target has been cleanly identified. Anyone framing BPC-157 as a defined receptor agonist is going past the published mechanism.^[2][6]
• Dose translation is unsupported. Published animal doses cover wide intraperitoneal and oral-drinking-water ranges in rats and mice. This article makes no attempt to translate them to a human dose. Sources offering specific "BPC-157 protocols" for humans are going outside the published data.

These gaps are not arguments against studying BPC-157. They are arguments against overselling it while the human evidence remains limited.

BPC-157 Research Record

BPC-157 belongs in the category of preclinical repair-signalling research peptides. The published record is dominated by rodent and in-vitro work, with one two-subject human safety pilot and no registered late-stage efficacy trial. Analytical documentation can describe a tested sample, but it does not close that evidence gap.

Researchers comparing the individual mechanisms can read the BPC-157 + TB-500 evidence review and the sister review of TB-500 (Thymosin Beta-4). The COA library explains what the site's archived third-party batch records do and do not establish.

Adjacent reading on this site: the KPV tripeptide review covers a small-peptide anti-inflammatory comparator with similar PCAC-docket exposure, and the GHK-Cu copper peptide review covers short-peptide extracellular-matrix research. None of those molecules is presented here as an approved therapeutic.

FDA PCAC votes July 23–24, 2026: six peptides recommended

The FDA Pharmacy Compounding Advisory Committee concluded its July 23–24, 2026 meeting by voting to recommend six of the seven candidate peptides for the 503A Bulks List, in free base and acetate forms where applicable: BPC-157 (8–6, one abstention; evaluated use: ulcerative colitis), KPV (8–6, one abstention; wound healing and inflammatory conditions), TB-500 (8–6, one abstention; wound healing), MOTS-c (7–5, two abstentions; obesity and osteoporosis), Epitalon (insomnia), and Semax (8–5, one abstention; cerebral ischemia, migraine, trigeminal neuralgia). Emideltide (DSIP) was the only candidate not recommended (6–7, one abstention).

The recommendations are advisory, and FDA’s own scientific review staff opposed inclusion of all seven peptides, so the agency may still depart from the committee. Formal notice-and-comment rulemaking — which commonly takes a year or more — must conclude before any 503A list change takes effect. No compound gained an approved indication, and the votes do not change the research-only status of any research-grade peptide. Sources: FDA meeting page and materials; McDermott Will & Schulte meeting analysis. Full tallies and rulemaking outlook: PCAC explainer.